The therapeutic targeting of TP-53 pathways represents a paradigm shift in precision oncology, offering unprecedented commercial opportunities driven by substantial unmet medical needs across diverse cancer indications. This comprehensive analysis examines a sector poised for remarkable expansion, supported by strong scientific foundations, advancing regulatory frameworks, and substantial...